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Abstract: 
Objective: The objective of  this study was to analyse the market share of  generic vs originator selective serotonin re-uptake 
inhibitors (SSRIs), and also compare market share of  different SSRIs in the private health care sector in South Africa, over a 
period of  4 years. 
Methodology: This was a retrospective, descriptive study that measured generic market volume as a percentage of  the total 
private SSRI market volume. Retail private sector sales data for six SSRIs available in the private sector in South Africa was eval-
uated. Sales data were obtained from various stages in the pharmaceutical supply chain, June 2009 – May 2013. 
Results: Generics constituted 86% and originators 14% of  the private sector market volume of  SSRIs. The share of  the market 
volume of  generic medicines increased by 29.93% over this 4-year period, while an overall increase of  27.86% in the ratio of  
generics to originators was observed. 
Conclusion: In line with policies, generic SSRIs hold a larger volume of  the market in the private sector in South Africa. 
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Introduction
Depression is a debilitating disorder in which patients 
have a low self-esteem and feel helpless, sad, and guilty.1 
According to the World Health Organisation, depression 
is affecting about 350 million people worldwide, there-
fore the demand for curbing and treating this mental 
health disorder is a global challenge. A recent South Af-
rican study reported that depression was the most com-
mon diagnosis, being present in nearly two thirds (63.9%) 
of  non-fatal suicidal patients seen in a large academic 
hospital.1
 
Depression is amongst the most commonly occurring 
chronic illnesses worldwide, and cost of  illness research 
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has shown that depression is associated with an enormous 
economic burden.2 In an attempt to curb high healthcare 
costs, governments have placed increasing importance 
on the provision of  low-cost, quality assured medicines.3 
The use of  generics is therefore often promoted in both 
the public and private sectors to reduce medicine costs, 
and increase product availability and consumer access.4 
The National Drug Policy for South Africa (1996) recom-
mends the use of  generics as a means of  reducing drug 
costs and expenditure. This contributes to a comprehen-
sive system of  procurement, distribution, drug informa-
tion and rational use at all levels of  the health care system 
in South Africa.
 
According to the FDA, generic medicine is identical, or 
bioequivalent, to an originator in terms of  dosage form, 
safety, strength, route of  administration, quality, perfor-
mance characteristics and intended use. The use of  ge-
neric pharmaceuticals is most frequent in industrialized 
countries, where prices for pharmaceuticals are usually 
high.5 Market share of  generic medicines have steadily in-
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creased worldwide: from 42% in 2005 to 49% in 2009 in 
Europe, and an increase from 19% in the USA between 
1984 and 2005.3
 
According to Kaplan, Wirtz & Stephens3 comparatively 
little is known about the private pharmaceutical market in 
middle-income countries, and even less is known about 
market dynamics between originator and generic versions 
of  the same product. Uptake of  generic medicines may 
be sub-optimal;4 barriers to the use of  generic medicines 
include lack of  incentives for physicians to prescribe ge-
nerics, economic disincentives for pharmacists to dis-
pense generics, and lack of  confidence in the quality of  
generic medicines on the part of  the patients and health 
professionals.4
 
Selective serotonin re-uptake inhibitors (SSRIs) selective-
ly and powerfully inhibit serotonin re-uptake and result 
in a potentiation of  serotonergic neurotransmission thus 
exhibiting therapeutic activity in depression, as well as 
anxiety, obsessional and impulse control disorders.6
 
This study therefore aimed to determine the trends in 
market volume of  generic vs originator SSRIs in the pri-
vate sector in South Africa, during the period June 2009 
– May 2013, also comparing market share of  different 
SSRIs during this period.
 
Methodology
This was a retrospective study based on private sector 
sales data obtained from the IMS Health (Proprietary) 
Limited (South Africa) information service(s) from April 
2009 to June 2013. IMS provides a useful database to the 
pharmaceutical and health care industries used by gov-
ernment, academics, drug plan administrators and phar-
maceutical companies.
 
Volume data represents purchase by the supply chain 
rather than actual consumption. Data for the period June 
2009 to May 2013 was analysed for this study.
 
The SSRIs included in the study were fluoxetine, fluvox-
amine, paroxetine, sertraline, citalopram and estcitalo-
pram; these SSRIs (both originator products as well as 
generics) are currently available in the private sector in 
South Africa.
 
The total generic market share was determined according 
to the method of  Kaplan, Wirtz & Stephens3: the per-
centage of  total private sector sales volume of  generic 
SSRIs divided by the total SSRIs private sector sales vol-
ume (originator + generic) for the period June 2009 – 
May 2013.
 
For the purpose of  this study a generic is identified as 
a pharmaceutical product intended to be interchange-
able with the originator brand products, manufactured 
without a license from the originator manufacturer and 
marketed after expiry of  the patent or other exclusivity 
rights.4
 
This study also measured market volume of  different SS-
RIs by measuring the percentage of  total private sector 
sales for a specific SSRI (originator + generic) divided by 
the total SSRIs private sector sales volume (originator + 
generic) for the period June 2009 – May 2013.
 
Results
The share of  the market volume of  generic medicines 
increased by 29.93% over this 45-year period, while an 
overall increase of  27.86% in the ratio of  generics to 
originators was observed. The market volume of  origina-
tor SSRIs remained relatively constant during this period 
(Figure 1).
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Fig 1: Comparison between the market volume of generics vs. originators for the 
period June 2009 – May 2013. 
The market volume for different SSRIs available in South 
Africa over the 45-year period of  the study is described 
in Table 1.
Fluoxetine, the first marketed SSRI, still holds a substan-
tial portion of  the market volume (29%). As to be expect-
ed, the generic product Nuzak®, priced at R35.74 / unit, 
has a much larger portion of  this market volume (45%) 
when compared to the originator, Prozac® (2%), priced 
at R427.12 / unit.
 
Citalopram and its enantiomer, estcitalopram, hold the 
majority of  the remaining market volume – citalopram 
accounts for 31% of  the market volume and estcitalo-
pram for 22%. Once again, the generic products have 
a larger portion of  the market volume with price most 
probably the most significant factor. There is a substantial 
price difference between the originator and top-selling 
generic citalopram products - Cipramil® (originator) is 
priced at R297.79 / unit vs R69.47 for a Cilift® (generic) 
unit; as well as the estcitalopram products - Cipralex® 
(originator) is priced at R426.34 / unit vs R175 for a Lex-
amil® (generic) unit.
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Table 1: Market volume of SSRI’s for the period June 2009 – May 2013. 
 
Fluoxetine Comprises 29% of total SSRI market volume for period June 
2009 – May 2013 
Prozac® (originator) 2% of market 






45% of market 
volume of fluoxetine 
Sertraline Comprises 9% of total SSRI market volume for period June 2009 
– May 2013 
Zoloft® (originator) 7% of market 






40% of market 
volume of sertraline 
Paroxetine Comprises 8% of total SSRI market volume for period June 2009 
– May 2013 








37% of market 
volume of 
paroxetine 
Fluvoxamine Comprises 1% of total SSRI market volume for period June 2009 
– May 2013 








63% of market 
volume of 
fluvoxamine 
Citalopram Comprises 31% of total SSRI market volume for period June 
2009 – May 2013 








73% of market 
volume of 
citalopram 
Estcitalopram Comprises 22% of total SSRI market volume for period June 
2009 – May 2013 
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Discussion
The cost savings of  increased use of  generic medicines 
can be substantial.3 Potentially, it is possible to improve 
cost-effective medicine use in the private sector if  origi-
nator brands were switched to the lowest-priced generic 
equivalents available.7 Results from this study show an 
increase in the market volume of  generic SSRIs, while 
there is no significant change to the market volume of  
originator SSRIs.
 
Although it should not be assumed that, if  market share 
of  an originator has decreased, the counterpart generic 
has increased, a previous study conducted in South Af-
rica found a higher number of  originators were replaced 
by their counterpart generic products.3 In low to middle 
income countries, originators that have come off  patent 
generally cost substantially more than do their generic 
equivalents7– this is also obvious in the prices of  SSRIs in 
South Africa as indicated above.
 
Despite the sharing of  the same principal mechanism of  
action, SSRIs are structurally diverse with clear variations 
in their pharmacodynamics and pharmacokinetic profiles. 
These pharmacological and pharmacokinetic differences 
underly the increasingly apparent important differences 
amongst the SSRIs.6 One of  the most important differ-
ences between the SSRIs is their potential to cause drug-
drug interactions through inhibition of  cytochrome-P450 
isoforms. Knowledge regarding the CYP-isoforms in-
volved in the metabolism of  these drugs may help antic-
ipate and avoid potentially dangerous drug-drug interac-
tions.8 These clinical important differences amongst the 
various SSRIs will impact on prescribing patterns and 
thus market volume of  the different products.
 
Fluoxetine, citalopram and estcitalopram claim the largest 
share of  the SSRI market volume in South Africa. Al-
though pharmacologically quite similar, there are subtle 
differences between the various SSRIs that might influ-
ence choice.
 
Fluoxetine, the first SSRI launched on the market, still re-
mains one of  the SSRIs with the highest market share in 
the private sector in South Africa despite some disadvan-
tages, including high drug interaction potential; common 
adverse effects such as headache, diarrhoea and anxiety; 
long half-life; and slow onset of  action.9
Citalopram and its enantiomer, estcitalopram, are the 
newest SSRIs available and together share the largest vol-
ume of  the SSRI market in the private sector in South Af-
rica. Citalopram, with a slightly larger share of  the market 
volume compared to estcitalopram, might be preferred 
by both prescribers and patients as it is selective and it 
is associated with decreased occurrence of  withdrawel 
symptoms.9 Estcitalopram is the most selective SSRI and 
has few adverse effects compared to other SSRIs; it has a 
rapid onset of  action, potent anxiolytic effects and is best 
tolerated.9
 
The remaining SSRIs claim a small portion of  the mar-
ket volume, which might be due to small but significant 
pharmacological differences. Sertraline has a low drug in-
teraction potential, however it has many adverse effects 
such as nausea, insomnia, diarrhoea and headache.9 Par-
oxetine has a moderate to high drug interaction potential 
and it has a highly variable half-life. Paroxetine is the most 
potent SSRI, but least selective for serotonin re-uptake 
receptors.9 It’s adverse effects include sexual dysfunction, 
weight gain and anti-cholinergic effects such as dry mouth 
and constipation. Paroxetine has a risk of  discontinuation 
syndrome – it has withdrawal like symptoms such as nau-
sea, headache, and flu-like symptoms, thus contributing 
to its low percentage of  consumption.9 Fluvoxamine is 
the SSRI with the lowest market share in South Africa. 
This drug is mainly used for obsessive-compulsive disor-
der. It has a risk of  discontinuation syndrome and it is the 
most sedating SSRI.9
 
Lastly, a large portion of  the private sector are covered by 
medical aid. Many medical aids use a maximum medical 
aid price (MMAP) system for drugs that are no longer 
controlled by a patent and are therefore available from 
many sources. Patients who wish to receive a branded 
version that costs more than the MMAP have to pay the 
difference in price themselves (an example of  a patient 
co-payment). In these cases, patients may opt for the ge-
neric product, covered by the medical aid, thus contribut-




Generic SSRIs hold a larger volume of  the market in the 
private sector in South Africa when compared to origina-
tor products. This is in line with policies, even within the 
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private health sector, to promote the use of  generics and 
decrease pharmaceutical expenditure. 
 
When it comes to choice between different SSRIs, these 
are based on price, prescriber and patient preference and 
pharmacological differences between the different SSRIs.
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